I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Find a Research Lab
David Graham Lab
The David Graham Lab studies the consequences of HIV interactions with the immune system, the resulting pathogenesis and how to sabotage these interactions. We apply advanced technologies like mass spectrometry to dissect processes at the molecular level. We are also actively involved in cardiovascular research and studies the ways proteins are organized into functional units in different cell types of the heart.
Major projects in our lab are organized into three major areas: (1) H/SIV pathogenesis and neuropathogenesis, (2) Cardiovascular disease, and (3) High technology development
Molecular and Comparative Pathobiology
David Thompson Lab
Researchers in the David Thompson Lab examine the outcomes of patients treated in intensive care units (ICUs), patient safety efforts, quality improvement efforts, and multidisciplinary teamwork and safety curriculum development. We're taking part in a study aimed at reducing hospital-acquired infections among cardiovascular surgery patients. Our investigators also participated in a clinical research collaboration that saw an 81 percent reduction in bloodstream infections related to central lines.
Dhananjay Vaidya Lab
Research conducted in the Dhananjay Vaidya Lab focuses on the prevention of heart disease, with special emphasis on cardiometabolic risk factors, genetics in high-risk families, cardiovascular epidemiology, statistics and vascular biology. We also provide consultation on study design as well as plan and oversee data analyses for projects supported by the Center for Child and Community Health Research.
Eliseo Guallar Lab
Research in the Eliseo Guallar Lab focuses on the epidemiology and prevention of cardiovascular diseases. We have a special interest in the roles played by mercury, arsenic, lead and cadmium in cardiovascular disease development. Our methodological interests include determining threshold effects in epidemiological studies and applying statistical methods to epidemiological problem-solving.
Elizabeth Selvin Lab
The Elizabeth Selvin Lab examines the intersection of epidemiology, clinical policy and public health policy. One of our key goals is to use the findings of epidemiologic research to inform the screening, diagnosis and treatment of diabetes, cardiovascular disease and kidney disease. Much of our work looks at biomarkers and diagnostics related to diabetes and diabetes complications. Our findings — linking hemoglobin A1c (HbA1c) to diabetic complications and identifying the role of A1c in diabetes diagnosis — have influenced clinical practice guidelines.
Ernesto Freire Laboratory
The Ernesto Freire Lab studies the use of novel drugs to treat disease. Our research has resulted in the development of a thermodynamic platform for drug discovery and optimization. Our aim is to achieve high binding affinity and selectivity as well as appropriate pharmacokinetics with the platform. We are currently focusing on drug targets such as HIV/-1 protease inhibitors (HIV/AIDS), plasmepsin inhibitors (malaria), HCV protease inhibitors (hepatitis C), coronavirus 3CL-pro protease inhibitors (SARS and other viral infections), HIV-1 gp120 inhibitors (HIV/AIDS), chymase inhibitors (cardiovascular disease) and beta lactamase inhibitors (antibiotic resistance).
Biophysics and Biophysical Chemistry
Felicia Hill-Briggs Lab
Research in the Felicia Hill-Briggs Lab focuses on assessment methods and clinical intervention in behavioral medicine, with an emphasis on patient self-management and outcomes in ethnic minorities with chronic diseases. We are interested in the application of problem-solving and decision-making models to self-management and health behavior change. Our recent research involves examining problem-solving training for cardiovascular disease risk self-management in African Americans with type 2 diabetes. We also have a long-standing interest in cognitive/neuropsychological processes in chronic diseases, translation of research to clinical practice settings and community-based settings, and evidence-based behavioral medicine.
The Foster Lab uses the tools of protein biochemistry and proteomics to tackle fundamental problems in the fields of cardiac preconditioning and heart failure. Protein networks are perturbed in heart disease in a manner that correlates only weakly with changes in mRNA transcripts. Moreover, proteomic techniques afford the systematic assessment of post-translational modifications that regulate the activity of proteins responsible for every aspect of heart function from electrical excitation to contraction and metabolism. Understanding the status of protein networks in the diseased state is, therefore, key to discovering new therapies.
D. Brian Foster, Ph.D., is an assistant professor of medicine in the division of cardiology, and serves as Director of the Laboratory of Cardiovascular Biochemistry at the Johns Hopkins University School of Medicine.
The Gabelli lab research is focused on structural, mechanistic and functional aspects of enzyme activation that play a role in the biology of human diseases such as cancer, parasitic infection and cardiovascular disease. Their work seeks to:
1. Understand how molecular events at the recognition level coordinate and trigger events in the cells
2. Translate structural and mechanistic information on protein:protein interactions at the cytoplasmic level into preventive and therapeutic treatment for human disease.
To achieve a comprehensive understanding, they are studying cytoplasmic protein-protein interactions involved in regulation of pathways such as PI3K and Sodium Voltage gated channels. Their research integrates structural biology and chemical biology and it is focused on drug discovery for targeted therapies.
Gail Daumit Lab
Research in the Gail Daumit Lab is devoted to improving overall health and decreasing premature mortality for people with serious mental illnesses, such as schizophrenia and bipolar disorder. We have conducted observational studies to determine and convey the burden of physical health problems in this vulnerable population, and are currently leading a randomized trial funded by the National Heart, Lung, and Blood Institute to test a comprehensive cardiovascular risk reduction program in people with serious mental illness.